SRAD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sportradar Group AG (SRAD) is not a good buy at this moment for a beginner investor with a long-term strategy. The stock is facing significant negative catalysts, including ongoing investigations, negative sentiment from analysts, and a bearish technical setup. Despite some positive financial growth in revenue, the company's net income has significantly declined, and the stock remains under pressure. It is recommended to hold off on investing until the situation stabilizes.
The technical indicators for SRAD are bearish. The MACD histogram is negative and expanding downward, RSI is at 17.426 indicating an oversold condition, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 12.825, with resistance levels at 15.472 and 18.119. Overall, the technical setup does not favor a buy at this time.
Revenue increased by 20.13% YoY in Q4 2025, indicating some operational growth.
Gross margin improved by 7.50% YoY, reflecting better cost management.
Investigations into potential securities fraud and allegations of aiding illegal gambling have significantly impacted investor confidence, leading to a 22% stock drop.
Analysts have downgraded the stock, citing concerns over revenue quality and business practices.
Net income dropped by -504.13% YoY in Q4 2025, raising concerns about profitability.
Bearish technical indicators and lack of positive trading sentiment from hedge funds or insiders.
In Q4 2025, Sportradar's revenue increased by 20.13% YoY to $368.89 million, and gross margin improved by 7.50% YoY to 49.46%. However, net income dropped significantly by -504.13% YoY to $4.4 million, and EPS remained flat at 0.01. The financial performance shows growth in revenue but severe profitability challenges.
Analyst sentiment is mixed to negative. Jefferies downgraded the stock to Hold with a reduced price target of $14, citing scrutiny over business practices and revenue quality concerns. Other analysts, such as Stifel and Truist, maintain Buy ratings but have lowered price targets. The stock faces a significant overhang due to ongoing investigations and negative sentiment.
